2 blue chip healthcare shares you should own

Every investor should consider these 2 healthcare giants.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The economy is made up of a number of different sectors and businesses. The healthcare industry is one of the best sectors to invest your money in my opinion.

Here are a few reasons why you should consider Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL).

Defensive earnings

Healthcare offers shareholders a defensive earnings profile because of how integral the product or service is.

People will value being alive and healthy over most other things in life.

CSL offers a variety of services like plasma products, vaccines and pharmaceuticals which users will all value over a trip to the movies and other lifestyle expenses.

Cochlear gives its users a life changing ability to improve their hearing with hearing implants.

Ageing demographics

There is a unique set of circumstances happening now and over the next few decades where the population of people older than 65 is going to significantly increase. This should be a big boost to all the companies that benefit from elderly customers. Cochlear and CSL could be two of the biggest winners.

International expansion

Australia has a small population and it doesn't offer much room for growth. If a business can successfully expand overseas then the world becomes their oyster.

CSL and Cochlear both earn a large majority of their earnings from overseas and I imagine this will continue to be the case as they grow in Europe and North America.

Time to buy?

Cochlear is trading at 38x FY18's estimated earnings and CSL is trading at 30x FY18's estimated earnings.

Both shares are wonderful businesses but I don't think they're buys at the current prices. I'd wait until they're both at least 15% to 20% cheaper before buying over the next six months.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »